HB-200 (Eseba-vec)
HPV16+ recurrent/metastatic Head and Neck Cancer
Key Facts
About HOOKIPA Pharma
HOOKIPA Pharma's mission is to develop novel immunotherapies that reprogram the immune system to combat cancer and infectious diseases. Its core achievement is the development of a proprietary, replicating arenavirus vector platform (VaxWave®/TheraT®) designed to elicit superior antigen-specific CD8+ T cell responses, a strategy validated by foundational Nobel Prize-winning science. The company's strategy focuses on advancing a clinical-stage pipeline in high-unmet-need areas like HPV16+ cancers and cytomegalovirus (CMV) while exploring partnerships to leverage its versatile platform technology.
View full company profileAbout HOOKIPA Pharma
HOOKIPA Pharma's mission is to develop novel immunotherapies that reprogram the immune system to combat cancer and infectious diseases. Its core achievement is the development of a proprietary, replicating arenavirus vector platform (VaxWave®/TheraT®) designed to elicit superior antigen-specific CD8+ T cell responses, a strategy validated by foundational Nobel Prize-winning science. The company's strategy focuses on advancing a clinical-stage pipeline in high-unmet-need areas like HPV16+ cancers and cytomegalovirus (CMV) while exploring partnerships to leverage its versatile platform technology.
View full company profile